報價延遲最少15分鐘:2026/04/21 20:02 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
98.16 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-9.73/-13.15
|
|
企業價值
2.94B
|
| 資產負債 |
|
每股賬面淨值
3.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
55.23M
|
|
每股收益
3.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255. |
